Draeger Receives FDA Clearance for Evita V800 Upgrade
TELFORD, Pennsylvania, June 22, 2026 Draeger, Inc., the U.S. headquarters of global medical technology leader Dräger, has announced that...
AI drug discovery AI healthcare artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
TELFORD, Pennsylvania, June 22, 2026 Draeger, Inc., the U.S. headquarters of global medical technology leader Dräger, has announced that...
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that the European Medicines Agency’s Committee for Medicinal Products for...
MUMBAI, India, April 24, 2026 Cipla Limited continues to reinforce its position as a leading global pharmaceutical company, advancing...
Langhorne, Pennsylvania, USA, April 7, 2026 MHRA Acceptance Marks Key Regulatory Milestone In a significant advancement for rare disease...
LANGHORNE, Pa., March 30, 2026 Savara Inc. has achieved a major regulatory milestone as the European Medicines Agency (EMA)...
